Takeda To Rely On M&A, Emerging Market Expansion To Offset Patent Losses
This article was originally published in PharmAsia News
Executive Summary
Japan's largest drug company Takeda hopes to minimize the impact of looming patent expirations in the U.S. by relying on mergers and acquisitions to increase its pipeline and extend its territory coverage, especially in emerging countries
You may also be interested in...
Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
TOKYO - Japan's leading pharma companies have made a number of high profile M&A moves in the past two years, and there are no signs that they are done with their pursuits. However, the number of attractive biotechs at the right stage of growth and value has decreased drastically
Japan's Western M&A Targets Drying Up? Astellas-OSI Bid Underscores Hostile Pressures - BIO Asia
TOKYO - Japan's leading pharma companies have made a number of high profile M&A moves in the past two years, and there are no signs that they are done with their pursuits. However, the number of attractive biotechs at the right stage of growth and value has decreased drastically
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.